SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

SALSS D.C. 2019

Presenting Companies
& Exhibiting Companies

APRIL 9 & 10 2019

Contents

PRESENTING COMPANIES

EXHIBITING COMPANIES

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

Presenting

Companies

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical-stage programs. The first two are therapeutic programs that target psoriasis (ABY-035) and rare Immunoglobulin G (IgG) - mediated autoimmune diseases (ABY-039). The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Our Products & Services

Affibody® molecules have very small size resulting in rapid tissue penetration and efficient low volume delivery of high molar doses of drug. With the modular ability for multispecific formats and robustness of the molecules, we create novel medicines.

ABY-035 is a novel IL-17A targeting agent, currently in Phase 2, which has been specifically designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life.

ABY-039 is a novel anti-FcRn antibody-mimetic, currently in Phase 1, which has been specifically designed to utilize the advantages of Affibody's technology platform to differentiate from competing antibody and Fc-based approaches. ABY-039 is a small protein ligand (~19 kDa, approximately an eighth of the size of an antibody) and has an in vivo half-life exceeding that of antibody-based approaches.

ABY-035 and ABY-039 are based on the Affibody® technology, which includes the Affibody® molecules (6 kDa size, no Fc-function) and Albumod™ platform, enables modified and enhanced pharmacokinetics through the albumin binding domain, offering a similar favorable distribution profile as albumin.

What makes us unique?

Our innovative Affibody® technology provides a creative and systematic platform to develop novel drug candidates. We combine this with a drive to challenge the status quo in clinical development, and with an extensive network of renowned researchers and clinicians to secure success at developing medicines that can shape the future of our industry.

Fundamental to this idea is our discovery and early research strategy where we ensure that we have a clear product vision based on unmet needs while focusing on indications and targets where the strengths of our Affibody® technology can be leveraged. We ensure a continuous inflow of high value projects and ideas through our extensive network of renowned researchers and clinicians, and constantly reach out to new thought leaders and potential collaborators to capture the future.

Why should you meet us?

Affibody is at a major inflexion point that aims to scale the company's drug development efforts and take the next step developing into an integrated biopharma company. We will also accelerate our outreach to thought leaders and potential collaborators. With this in mind we are now working to increase the awareness of our company. The aim of this is to find potential partners and investors to join the scaling of the company's future operations.



ADVANCING MODERN INNOVATIVE MEDICINE THROUGH OUR LONG-TERM COMMITMENT TO DEVELOP AND COMMERCIAL-IZE THE NEXT GENERATION OF MEDICINES.

Key Team

David Bejker, M.Sc. | CEO

~20 years in the biotech industry. Involved in numerous transactions, primarily financings and re-financings of biotech companies.

Johan Stuart, M.Sc., CFO

~20 years' experience as CFO of listed and unlisted companies. Involved in three Initial Public Offerings.

Karin Nord, Ph.D., SVP Research Operations

Dr. Nord is a co-founder of Affibody. Lead author of the first report on Affibody® molecules, published in Nature Biotechnology in 1997.

Fredrik Frejd, Prof., Ph.D., CSO

~20 years' experience in life science research. Professor at Uppsala University.

SALSS Contact

David Bejker, CEO
david.bejker@affibody.se

Fredrik Frejd, CSO
fredrik.frejd@affibody.se

Affibody AB
Gunnar Asplunds Allé 24, SE-171 69 Solna, Sweden.

www.affibody.se

BIOARCTIC

BioArctic AB is a clinical-stage biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and complete spinal cord injury (SCI). Founded in 2003, BioArctic is based around clinical discoveries that demonstrated the involvement of soluble toxic aggregated forms of amyloid-beta (Aβ) protofibrils in disease pathogenesis.

Our Products & Services

BioArctic's lead clinical program in AD is partnered with Eisai, targeting protein misfolding as a common causal pathway in neurodegeneration. BAN2401 (and a backup) are anti-Aβ antibodies, selective for the soluble protofibrils, to eliminate neurotoxic Aβ species. The positive 18-mo results from BAN2401 Phase 2b study demonstrated an effect on clinical function as well as reduced aggregation of amyloid-beta in the brain with good tolerability.
This is the first late-stage study successfully demonstrating potential disease-modifying effects on both cognition and biomarkers.
AbbVie has licensed our alpha-synuclein antibody portfolio for PD and other indications. The first clinical study with ABBV-0805 is planned to start in 2019.
SC0806 is a unique biodegradable device with FGF1, for the regenerative treatment of Complete SCI.

What makes us unique?

BioArctic has scientific competence, experience developing drugs from idea to market and a solid cash position with more than SEK 1 billion. Collaborations with universities are of great importance to the company together with global partners in Alzheimer and Parkinson projects.
Through long-term collaboration agreements with global pharmaceutical companies, BioArctic has demonstrated high skill level and great ability to deliver innovative pharmaceutical projects.

Why should you meet us?

The project portfolio consists of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. We are interested to meet investors and potential licensing partners for our innovative program.



CREATING DISEASE-MODIFYING TREATMENTS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISORDERS

Key Team

Gunilla Osswald, PhD
| President & CEO
30+ years experience in drug development. Formerly VP, Neurodegeneration Disease Modification, Astra Zeneca

Lars Lannfelt, MD, PhD
| Founder, Senior Vice President
Senior Professor at Uppsala University. Member of the Royal Swedish Academy of Sciences

Hans Basun, MD
| VP Clinical Development & CMO
20+ years pharma industry experience in leading positions in clinical research at Astra Arcus /AstraZeneca

Christer Möller, PhD
| VP Pre-clinical Development & CSO
20+ years drug development and clinical trial experience, including at Zymenex A/S

SALSS Contact

Gunilla Osswald, President & CEO
gunilla.osswald@bioarctic.se
+46 8 695 69 30

BioArctic AB
Warfvinges väg 35 SE-112 51 Stockholm Sweden.

www.bioarctic.se

CELLINK

CELLINK is the first bioink company in the world and the leading 3D Bioprinter provider focusing on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic treatments. Founded 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it.

Our Products & Services

CELLINK develops and markets both bioprinters and bioinks, enabling the creation of complex 3D tissue structures. Our flagship BIO X is a next generation 3D bioprinter, bringing scientists yet closer and faster to a desired future of medicine. BIO X is a complete stand alone unit with a 7" touch screen and HEPA filtered aseptic printing area, within a small lab footprint. User exchangeable, intelligent printheads make it possible to bioprint a wide range of bioinks and cells with minimal effort. A bioink is a biomaterial that is suitable for bioprinting with cells and provides a temporary or permanent support and an aqueous 3D environment with biologically relevant chemical and physical signals, mimicking the natural extracellular matrix environment.

When you are looking for an ideal solution to all your 3D Bioprinting and 3D cell culturing needs you can count on CELLINK to deliver the results you are looking for. CELLINK currently provides more than 50 different ready-to-use bioinks for various applications, with more bioinks in development to broaden the spectra.

What makes us unique?

We are a team of entrepreneurs, scientists, engineers - pioneers, pushing the limits for what's possible, paving the way for the future of regenerative medicine. With our 3D bioprinters we hope to open the possibility for more extensive medical research. BIO X is the new go-to bioprinter for life science companies, researchers and innovators around the world. CELLINK is the first universal bioink ever developed and is currently being used by hundreds of labs, in more than 50 countries worldwide.

Why should you meet us?

If you are interested in changing the future of medicine through better technologies enabling researchers to fail faster and achieve more with less or if you are interested in supporting or investing in to these technologies, come talk to us!

Enabling researchers and scientist to 3D-Bioprint human tissues and organs.

Key Team

Erik Gatenholm
| CEO & Co-founder

Hector Martinez
| CTO & Co-founder

Gusten Danielsson
| CFO & Co-founder

Oriana Zoghbi
| US Sales Director

SALSS Contact

Gusten Danielsson, CFO
gd@cellink.com
+1 857 332-2138 | +46 (0)70 991 86 04

Cellink AB
Arvid Wallgrens Backe 20, Gothenburg, 41346 Sweden.

www.cellink.com

ELYPTA

Elypta is an innovative molecular diagnostic company, commercializing the world's first pan-cancer liquid biopsy based on metabolism.

Our Products & Services

Elypta's liquid biopsy is based on the measurement of a proprietary panel of metabolites, glycosaminoglycans (GAGs), found to have broad diagnostic potential in oncology. The platform consists of two components:

+ IVD assay kits for measurement of the comprehensive GAG profile in blood and urine specimen
+ Cloud-based software for automated interpretation of GAG measurements and generation of clinically useful scores.

The kits can be used un-changed across cancer with signatures specific to different cancers and applications added to Elypta's software as they are validated. There is a broad opportunity space from screening to follow-up and Elypta has analysed over 1800 samples in 14 cancers to date. Elypta has ongoing prospective trials in kidney, prostate, bladder and lung cancer.

What makes us unique?

The liquid biopsy space is often associated with the many efforts based on ctDNA or CTCs as biomarkers. Elypta is bringing a novel and proprietary biomarker panel with pan-cancer relevance to market. Furthermore, it is based on metabolism rather than genetics. The key features are exceptional sensitivity to cancer also in the earliest stage of disease.

Why should you meet us?

The European Union recently awarded Elypta a highly competitive Horizon 2020 grant of €2.3m to fund the first ever multi-center prospective diagnostic trial in kidney cancer with leading centers in US & EU. Elypta is now raising additional capital from investors and is also starting to seek partnerships to fully exploit the potential across the diagnostic spectrum.



ADVANCING CANCER DETECTION

Key Team

Karl Bergman, MSc Bioengineering, MBA | CEO

Former Principal at Arthur D. Little, serving global pharma, diagnostics and healthcare clients.
Former Chief Digital Officer at Praktikertjänst, Sweden's largest private healthcare provider.

Francesco Gatto, PhD in Systems Biology | CSO

Inventor and scientist behind Elypta's tech.
Named Pioneer of the year & Top 35 Innovator Under 35 by MIT Technology Review EU in 2018.

SALSS Contact

Karl Bergman, CEO
karl.bergman@elypta.com
+46 73 262 53 33

Francesco Gatto, CSO
gatto@elypta.com
+1 (858) 247 9006

IMMUNICUM
INNOVATION IN IMMUNO-ONCOLOGY

Immunicum (Nasdaq Stockholm, Ticker: IMMU.ST) is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies, to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumors.

Our Products & Services

Ilixadencel: allogeneic dendritic cells producing chemokines & cytokines.
+ Recruit and activate patient's own immune cells in tumor tissue.
+ Induce local tumor cell death
+ Prime immune system against neoantigens in tumor tissue.

What makes us unique?

+ Recent capital raise SEK 351 M ($ 39 M) with institutional investors finances the company towards the end of 2021 through several value-inflection points.
+ Phase Ib/II multi-indication (ILIAD) study with checkpoint inhibitors FDA approved and initiated; first safety and dosing results during 2019.
+ Recent collaboration and supply agreement with Merck KGaA (Germany) and Pfizer to supply Bavencio® (avelumab) for Phase II of ILIAD study.
+ Phase II RCC (MERECA) study fully enrolled with 88 patients in US and Europe; top-line results on overall survival expected in Q3 2019.
+ Previous Phase I/II results in RCC demonstrated extended median overall survival of 48 months vs. historical control of 15 months.

Why should you meet us?

IMMUNO-ONCOLOGY
+ Fastest growing pharma market.
+ Active deal-making by big pharma.
+ Backbone combination product.

OFF-THE-SHELF CELL THERAPY
+ Unique & differentiated mechanism.
+ Robust manufacturing for development.
+ Commercial scale development initiated.

ADVANCED STAGE
+ Phase II in kidney cancer with topline results in Q3 2019.
+ Excellent safety in over 90 patients.
+ Studies in US and 8 EU countries.

WELL FINANCED
+ SEK 351 M ($39 M) recent capital raise.
+ Runway until end of 2021.
+ Strong syndicate of institutional investors.



ADVANCING A NOVEL AND UNIQUE IMMUNO-ONCOLOGY APPROACH TO TREAT SOLID TUMORS

Key Team

Carlos de Sousa
| Chief Executive Officer

Peter Suenaert
| Chief Medical Officer

Michaela Gertz
| Chief Financial Officer

Sharon Longhurst
| Head of CMC

Alex Karlsson-Parra
| Chief Scientific Officer

Sijme Zeilemaker
| Senior Director Business Development

Margareth Jorvid
| Head of Regulatory & QA

SALSS Contact

Carlos de Sousa, CEO
carlos.desousa@immunicum.com

Immunicum AB
+46 8 732 84 00 | Östermalmstorg 5, 114 42 Stockholm

www.immunicum.se

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

Ziccum formulates and patents new versions of liquid vaccines and biologics—as dry powders. This makes them robust and highly cost-effective to transport. The result is more vaccines getting to the people who need them most, plus new patents and markets.
Ziccum AB (publ) develops robust dry powder formulations of biologic drugs and vaccines that currently only exist in liquid, or freeze-dried form. This increases access to vaccines and biologic therapies in existing markets—and opens up new ones. Ziccum's patented technology Laminar-Pace was invented by Karolinska Institutet Assoc. Professor Per Gerde, a world authority on dry powder aerosols.

Our Products & Services

VACCINES:
1-in-5 children worldwide still don't receive even basic vaccines and 20 million children are dangerously under-vaccinated (WHO). We have a solution. We develop vaccines as robust, temperature-resistant dry powders. That means they require no refrigeration or cold chain during transportation or storage, significantly reducing vaccination costs. Ziccum's dry-powder version of Adenovirus stayed active at +40° C for over a week, easily meeting the WHO's CTC (Controlled Temperature Chain) classification requiring vaccines to tolerate temperatures of +40° C for three days to increase the world's vaccinated population.

BIOLOGICS:
New injectable biologic therapies are highly targeted and effective, and growing fast. But 80% are still formulated as liquids, making them costly to transport and administer. We have a solution. New dry-powder biologic treatments are both easier to transport and more robust for research. We are patenting new dry powder forms of biologics including proteins, antibodies and viruses.

What makes us unique?

Most current drying methods involve extreme temperatures, exposing fragile substances to freeze drying or baking at -80 °C or +80 °C. This means there is little chance of delicate temperature-sensitive biologic substances like antibodies, viruses or proteins remaining active after being dried.
Ziccum's LaminarPace technology air-dries substances at room temperature. This makes it ideal for handling sensitive substances. High-potential biological research materials and delicate injectables can be transported and stored cheaply and safely, with the active ingredient remaining active, after being gently micronized. When rehydrated with water the active dry powder therapy or substance is ready to be administered.

Why should you meet us?

Harnessing the Intellectual Property rights on new dry powder versions of vaccines and biologics is a key component of Ziccum's business plan. We aim to seek patents on all of the new dry-powder versions we're currently developing. Access to our patents via licenses will provide a powerful competitive edge to biologic pharma developers in a market forecast, including gene and cell therapies to be worth $1.2 trn by 2024.

DRY FORM ACCINES AND BIOLOGICS: TOUGH, TRANSPORTABLE, TEMPERATURE-RESISTANT.

Key Team

Göran Conradsson | CEO
MSc Chemical Engineering. Driven business development of more than 15 Life Science technologies, plus senior sales, marketing and business development roles at Pharmacia (now GE), Biacore and BioInvent amongst others. Whilst at Pharmacia Göran was involved in large-scale chromatography for the production of protein-based therapies.

Fredrik Sjövall | Chairman
M.Sc. Automation Engineering, MSc Business Development.
Previously CEO of Inhalation Sciences, responsible for the company's successful listing in 2017. Chairman of Inhalation Sciences since May 2018. Previously served as Chairman of Hemcheck AB, listed on Nasdaq First North, and CEO of PharmaSurgics AB and Lipopeptide AB (now merged with Promore pharma AB). Current roles: Chairman of the Board of Inhalation Sciences, Board member of Axelero AB and Lipidor AB.

SALSS Contact

Göran Conradsson, CEO
conradson@ziccum.com
+46 70 961 5599

Exhibiting
Companies

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

01

AVRA's first planned medical robotic system is targeting the rapidly expanding market for skin resurfacing, automating the controlled delivery of microneedling to stimulate remodeling.

Founded in 2015, AVRA Medical Robotics is a development-stage public company based in Florida. Pioneering a new generation of semi-autonomous medical robots around innovation in image-capture, navigation and tissue targeting, AVRA aims to build a leading franchise in the expanding robotic surgery market (CAGR +11.34%* to 2020).

Our Products & Services

Currently "medical robotics" generally refers to computer-assisted surgery, with humans operating a remote surgical device via a console are in fact not robots. AVRA's efforts have been dedicated towards constructing a novel and truly robotic single-armed platform for the field of aesthetics, skin and wound care, as well as
dermato-plastic surgery. Our first design integrates software, image guidance, navigation and targeting systems, to allow for autonomous needling of skin.
AVRA has assembled a team of expert robot engineers, scientists, industry consultants, and physicians to advance a new era in medical robotics, vastly different than current master-slave systems designed in the 1980's. AVRA's partnerships with the University of Central Florida (UCF) and German Aerospace (DLR) for the past decade remain a
cornerstone of our continued leadership in this field.

What makes us unique?

The future of surgery will be determined by success in gaining precision access to any area of the human body with the smallest incisions and deploying therapies to specific tissues, glands and organs. Limitations in conventional surgeries are demanding more autonomous, intelligent robot systems that go beyond the capabilities of a human being.
Our current focus on skin represents a large market for our technology because it is a key organ that needs continual maintenance and care. AVRA's platform focusing on needling technology represents a key breakthrough in aesthetics, wound-care, and autonomous drug delivery platforms. Integration of artificial intelligence and augmented reality will allow for a new paradigm in surgical training, planning and treatment.

Why should you meet us?

AVRA has recently filed its S-1 to become a publicly traded company and is ready to meet investors interested in the opportunities presented by our launch of a new generation of surgical robots capable of delivering innovative therapies directly to specific organs, glands and tissues.

PIONEERING SEMI-AUTONOMOUS MEDICAL ROBOTS FOR MINIMALLY AND NON-INVASIVE SURGERY.

Key Team

Barry F. Cohen | CEO & Founder
50 years' experience in managing private and public industrial companies and as a securities executive.

A. Christian Schauer | CFO
Decades of experience in senior management includ- ing as Chairman, President, and CEO of PharmOptima; CEO of Triple S. Plastics and CEO of Clausing Corporation.

Ray Powers, PhD, MBA
Executive within the Bell System for 30 years. C-level positions in the technology sector in both private and public companies.

Alexandre S. Clug, MBA
VP Business Development.
Successful CFO and CEO of various businesses Latin America, and Europe.

SALSS Contact

Barry F. Cohen, CEO
bcohen@avramedical.com
[+1] 866 205-4430

AVRA Medical Robotics, Inc.
3259 Progress Drive, Suite 112A, Orlando, FL 32826 USA.

www.avramedicalrobotics.com

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

COGNITO THERAPEUTICS

02

A unique and totally non-invasive method using sensory stimulation to activate microglia cells to remove beta amyloid plaques, characteristic of the brains of Alzheimer's disease patients.

Founded in 2016 and based in Cambridge, Massachusetts, Cognito Therapeutics is a clinical-stage startup developing a non-invasive treat- ment to restore gamma brain wave function, which plays a role in cognition and neurodegenerative conditions. The company received a Series A financing from Morningside Venture Capital in 2016.

Our Products & Services

Alzheimer's disease (AD) is a progressive neurodegenerative condition that remains one of the most serious and rapidly developing health challenges at an individual, family and societal level. In the US, an estimated 46.8 million patients are living with Alzheimer's.
Cognito's patented technology is based on discoveries at MIT's Dept. of Brain and Cognitive Sciences, which showed that pulsed light stimulation of the brain could activate an immune response by microglia cells to remove beta amyloid plaques, characteristic of the brains of AD patients. Following multiple Phase 1 clinical studies, Cognito is actively enrolling in two Phase 1/2 clinical trials to evaluate the effects of its therapy on patients with MCI and mild- to moderate-AD.
Rather than being exclusively focused on prevention and cure, Cognito aims to pioneer a new model of chronic disease management and care for AD and other neurological conditions with an in-home treatment platform, for use by a patient and their care partners to mitigate symp-toms.

What makes us unique?

Cognito's unique and totally non-invasive method, based on stimulating neurons with light pulsed in 40Hz range, at the optimal gamma rhythm amplitude has been exclusive licensed from MIT by Cognito Therapeutics on a worldwide basis. Prior to being published (Nature, Dec 2016), Cognito filed 40+ provisional patents to develop a significant IP portfolio to protect this new therapeutic area and additional indications.
Our senior management team has 50+ years in combined experience in the successful develop-ment medical devices through regulatory clearance and commercialization.

Why should you meet us?

Cognito is looking for commercial partners and to raise further financing around clinical development and validation of its approach and devices, and services, which will emphasize the importance of daily quality of life, for both patients and caregivers.



BREAKTHROUGH SENSORY STIMULATION THERAPY TO TREAT ALZHEIMER'S DISEASE.

Key Team

Li-Huei Tsai, Ph.D | Founder
Picower Professor of Neuroscience and Director of MIT's Picower Institute of Learning and Memory.

Ed Boyden, Ph.D | Founder
Professor of Biologi- cal Engineering and Brain and Cognitive Sciences at the MIT Media Lab and MIT McGovern Institute.

Zach Malchano | President
10+ years experience in R&D of innovative medical technologies.

Martin Williams | VP, BD and Marketing.
10+ years of experience across medical device development.

Fred Tobia | VP, Clinical & Regulatory Affairs and Quality Assurance.

SALSS Contact

Zach Malchano, President
zmalchano@cognitotx.com
[+1] 617.308.5943

Cognito Therapeutics, Inc.
1218 Massachusetts Ave, Suite 200 Cambridge, MA 02138.

www.cognitotx.com

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2019

DemeRx

Addressing the billion-dollar market and high unmet need for medically-assisted detoxification of opioid-dependent persons.

DemeRx is a clinical stage company advancing two lead drug candidates as medication-assisted therapies for opioid addiction. Our natural product lead drug – Ibogaine – is an indole alkaloid from equatorial Africa, which blocks opioid withdrawal symptoms and drug cravings, helping addicts to transition to sobriety. The Company has developed a robust IP portfolio around Noribogaine, the principal active metabolite of Ibogaine.

Our Products & Services

DemeRx has demonstrated that a single dose of Ibogaine is sufficient to detoxify opioid-dependent persons and diminish drug cravings for extended time periods. DemeRx has assessed the safety, pharmacokinetics, and pharmacodynamics of Ibogaine and Noribogaine in normal healthy volunteers and in patients with opioid abuse problems.
We plan to advance Ibogaine as a medication-assisted opioid detoxification for use in medically supervised inpatient settings. Noribogaine will be developed for office-based opioid dependent withdrawal treatment and for patient detoxification of incarcerated addicts.
Ibogaine and Noribogaine may offer advantages for patients suffering from opioid use disorder, including an increase retention in treatment, decrease in illegal opioid use, decrease in mortality, and a decrease in risk behaviors related to HIV and hepatitis C.

What makes us unique?

Opioid addiction is an unmet medical need. DemeRx is advancing two drug products to address the current opioid crisis. The rise in the number of people addicted to heroin and prescription opioids is a major driving factor for fast-track development and marketing of addiction drugs. Ibogaine and Noribogaine are non-addicting alternatives to the currently available opioid medications - Methadone and Buprenorphine that dominate the 1.2B opioid addiction market.

Why should you meet us?

The Company plans to raise funds for US FDA approved clinical trials of Ibogaine and Noribogaine. We will advance the Expanded Access (Compassionate Use) of Ibogaine for patients seeking opioid detoxification under the new Patient's Right-to-Try initiative.
DemeRx plans to fast track Noribogaine to a pivotal Phase 2 trial hence we are interested to speak to potential industry partners and investors.



DEVELOPING NON-ADDICTIVE TREATMENTS FOR DRUG ADDICTION.

Key Team

Deborah Mash PhD | CEO & Founder
Neuroscientist, Inventor and Entrepreneur. 25+ yrs experience in the field of addiction neurobiology and NCE development.

Richard Serbin | Executive Chairman
Global strategy advisor and entrepreneur with credentials in pharmacy and law. 40 yrs service as an FDA regulatory and patent attorney in the healthcare industry

John Thomas | Chief Financial Officer
Decades of experience in senior management in biotech and healthcare fields.

Robert Reder MD | Vice President & CMO
Expertise at every stage of the pharma lifecycle including opioid medications

Michael Karukin PhD | COO
20+ yrs pharma, CTM & REMS experience

SALSS Contact

Deborah C Mash PhD, CEO & Founder
dmash@demerx.com
[+1] 305.753.2175

DemeRx, Inc.
1951 NW 7th Avenue, Suite 300 Miami, FL 33136 USA.

www.demerx.com

GERAS SOLUTIONS



Geras Solutions (Geras) is a mHealth tool for individuals with a risk of, or a diagnosis of, age-related cognitive diseases such as dementia. The product is in development through key collaborations with clinicians, policy makers, key opinion leaders, caregivers, and patients. Geras' goal is to cover each step of the dementia lifecycle and provide adequate access to dementia healthcare via a digital platform.

Our Products & Services

Geras Solutions has a clear mission – to transform the lives of those impacted by dementia. We make this a reality by providing our digital solutions – Geras Clinic, Geras Support and Risk Reduction, which use AI and Machine learning processes, interpreted by specialists, to guarantee clinically tested dementia support modules.

+ Risk reduction: A digital tool that empowers users to lower their risk of dementia, over time, through lifestyle changes.

+ Geras Clinic: Diagnostic decision support through evidence-based clinical tests with specialist access via video chat.

+ Geras Support: Disease management and support for patients, relatives and caregivers, with follow-up after diagnosis, via video chat and other digital tools.

What makes us unique?

Geras Solutions is an AI-based diagnosis support tool that can detect cognitive impairment, provide specialist follow up support and offers individuals tools to prevent, maintain and delay cognitive decline and dementia through lifestyle interventions and modifications, encouraging individuals to track and manage their health.

These solutions are designed to be cost effective and easily accessible for patients while providing access to dementia specialists. By lowering the threshold to receive a dementia diagnosis and providing adequate support to dementia stakeholders, we can reduce the global non-detection rate of dementia around the world.

Why should you meet us?

Dementia is a global epidemic with more than 47 million diagnosed cases, 9.9 million new individuals diagnosed each year and an annual cost of over $1 trillion. An estimated 75% of individuals living with dementia have not received a formal diagnosis. As such, we truly believe that the digitisation of these fields and care will be necessary to provide adequate support and relief to an ageing global population exponentially impacted by dementia.

The Geras tool is currently undergoing clinical trials at the Memory Clinics at the Karolinska University Hospital and follows international dementia diagnostic guidelines. The device is CE marked, and we are now preparing for launch in Sweden and China during 2019.

We currently seek potential partners and investors looking to join our mission to make a difference and help individuals impacted by dementia.

TRANSFORMING LIVES OF MILLIONS IMPACTED BY DEMENTIA AROUND THE GLOBE.

Key Team

Haza Newman | CEO

Victor Bloniecki Kallio, MD | Clinical Content Manager

Gisselle Avila | Digital Media Coordinator

Vladimir Osipov | CTO

Bo Mattsson | Chairman

SALSS Contact

Haza Newman, CEO
+46 70-325 6418

Geras Solutions
Gyllenstiernsgatan 12, 115 26 Stockholm

www.gerassolutions.com

HypoSpray Pharma is a private company focused upon developing, licensing and commercializing proprietary drugs for safe, rapid and bioavailable transdermal dosing. Based in US, HypoSpray products are applied with a fine mist that disappears through the skin in seconds, achieving a safe and rapid systemic deliveryunavailable by any other means.

Our Products & Services

HypoSpray Pharma's transdermal delivery platform is patented and designed to achieve systemic bioavailability for a broad array of therapeutic drug candidates of up to 6,000 Daltons. The Company licenses the HypoSpray™ system and is developing the following products:
+ Testagen® is the Company's spray-on testosterone product. Testagen is absorbed rapidly and reduces the drug transference risk of the leading $1 billon dollar product, Androgel® from 24 hours to less than 20 minutes. Patients using Testagen can apply it anywhere on the skin and they will not need to wait eight hours before exercise, a shower, or intimate relations. The testosterone market exceeds $2 billion annually.

+ EPI-MistTM HypoSpray® is the Company's spray-on epinephrine product with bioavailability and bioequivalence that is expected to compete with the infamous EpiPen®. A costly injector needle is replaced with a gentle mist and the reassurance of rapid action of HypoSpray Epinephrine. Rapid intervention epinephrine is a nearly $2 Billion market annually but only 1 in 10 prescriptions are filled.

+ LevellorTM HypoSpray® is the Company's spray-on insulin product. Early clinical data shows that HypoSpray Insulin has the bioavailability and bioequivalence data to support its utility in the management of blood glucose. Without needles or nose sprays, HypoSpray® Insulin has the potential to engage the body's natural regulation of glucose. Insulin is a $75 Billion market.

+ Diclo-MistTM HypoSpray® is the Company's spray-on NSAID or Non-Steroidal Anti-Inflammatory, for the management of pain. HypoSpray® DC is diclofenac sodium, a powerful, non-opioid NSAID. Because HypoSpray DC is a fine mist applied to the skin, the gastric tolerance and toxicity typically associated with NSAID's is eliminated while offering the potential to modulate orthopedic and nerve pain. NSAIDs in this class are a $10+ Billion market.

What makes us unique?

HypoSpray Pharma's proprietary technology presents safe drug therapy in the most comfortable way conceivable. Systemic therapeutic doses are rapidly achieved and maintained without injection pain, and without stomach, nasal or bronchial irritation. In minutes, the mist flashes off the skin leaving the area free from topical residue, adhesives or restrictive patches.

Why should you meet us?

We currently collaborate with companies in Alzheimer's disease and autism where transdermal delivery is optimum. We collaborate with research institutes at St. Bartholomew's and Queen Mary's Medical College in London, and the University of London. In the US, we are collaborationing with the University of Florida and Scripps. Each of our markets exploits the HypoSpray technology in a way that dramatically improves outcome for already proven drug activity in very large markets.

DEVELOPING, LICENSING AND COMMERCIALIZING PROPRIETARY
DRUGS FOR SAFE, RAPID AND BIOAVAILABLE
TRANSDERMAL DOSING.

Key Team

Steven Eror | Executive Chairman
Steven Eror is a seasoned business builder and business development professional with leadership in predictive analytics, drug delivery, medical devices, business development, entrepreneurship, and strategic planning.

Kenneth Kirby | CEO & President
Keneth is a recognized pioneer in transdermal delivery since 1990. He has directed more than seven human drug trials. Mr. Kirby holds a B.A. in medical studies from Florida State University. He is a member of Phi Beta Kappa and the American Chemical Society.

SALSS Contact

Steven Eror, Executive Chairman
801.631-7288.

REDSENSE medical

Saving lives by revolutionizing blood loss detection with a patented core technology that utilizes fiber optics.

Founded in 2006, Redsense Medical is a publically listed innovative blood detection company. Redsense Medical is headquartered in Halmstad, Sweden, with a subsidiary in the US, Redsense Medical inc. and a distributor network covering Europe.

Our Products & Services

+ Redsense Medical has developed a hemodialysis monitoring system that can detect the very first sign of a blood leak using patented fiber optic technology. An alarm is triggered when the sensor comes into contact with blood so one can address the issue immediately and stop the blood flow.

+ Redsense also follows IEC Public Available Standard (PAS) 63023; if the dialysis machine does as well, these devices can connect and communicate and the blood flow will be stopped automatically when blood is detected.

+ Redsense is easy to use and offers both a venous fistula and central catheter solution. The Redsense system is available for all dialysis providers and is the only hemodialysis blood leak detection system that is both CE market and FDA cleared for sales in the US.
Redsense recently also added new technology patents to its portfolio, which will allow for a whole new range of detection systems across industries.

What makes us unique?

Redsense has developed and patented technology that consists of using light and fiber optics to detect and distinguish fluids. New technology was recently added to our already impressive patent portfolio, which will allow us to further revolutionize medical detection and monitoring systems and save lives.

Why should you meet us?

Our current products are gaining major global traction as a new standard for the best possible safety during hemodialysis treatment in both hospital settings and in the home. The system is adopted by the two largest hemodialysis providers in the US, as well as by three of the top five US clinics. Further, our new technology is sparking much interest and excitement to be adopted across different markets.



LET REDSENSE KEEP AN EYE ON YOUR VENOUS ACCESS.

Key Team

Patrik Byhmer, MSc | CEO & Co-founder

Brendan Kane, BSc | US Director of Sales

Jane Hurst, RN, CLNC | US Clinical Director

Sebastien Bollue, MSc | Commercial Operations Manager

SALSS Contact

Patrik Byhmer, CEO & Co-founder
patrik.byhmer@redsensemedical.com
+46 703 572 164

Hansa Biopharma is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.
Hansa Medical is a listed European biopharmaceutical company developing a proprietary enzyme technology platform for IgG-mediated rare, acute autoimmune conditions and cancer. Our lead program enables kidneytransplantation in difficult to transplant patients, with additional clinical studies ongoing for the treatment of several acute and chronic autoimmune conditions.

Our Products & Services

Our lead program IDEFIRIX™ (INN: imlifidase) enables kidney transplantation in difficult to transplant patients, with additional clinical studies ongoing for the treatment of several acute and chronic autoimmune conditions. Our R&D program is advancing our next generation of immunomodulatory enzymes to further extend the applications for our unique technology.

What makes us unique?

Hansa Biopharma is harnessing its unique and proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions.

Why should you meet us?

Based on our unique and propriatery enzyme technology we are creating sustainable partnerships with the global scientific, medical patient and investment communities.

DEVELOPS & COMMERCIALIZES IMMUNOMODULATORY ENZYMES FOR THE TREATMENT OF LGG-ANTIBODY MEDICATED CONDITIONS, TRANSPLANT REJECTIONS & CANCER

Key Team

Søren Tulstrup | Pretsident & CEO
Mr Tulstrup has broad and extensive background as senior executive in the global biopharma industry.

Vincenza Nigro | VP Global Medical Affairs
Ms Nigro holds more than two decades of international, life sciences industry expertise in medical affairs, clinical development and commercial leadership roles.

Christian Kjellman | Senior VP R&D and Chief Scientific Officer
Dr Kjellman holds more than two decades of immunology focused research and development and has been responsible for the R&D at Hansa since 2008.

Henk Doude van Troostwijk | VP Commercial Operations
Henk has extensive management experience in sales and marketing in the areas of transplantation and orphan drugs.

SALSS Contact

Emanuel Björne, Business Development and Investor Relations
emanuel.bjorne@hansabiopharma.com
+46 70 717 5477

MEDICERA
NEW MEDIC ERA

New Medic Era is a Swedish company with a vast portfolio of medical devices. The company operates worldwide through distribution to practitioners in the medical aesthetic field. Founded in 2004, the company focus is to develop products for the ageing population, who not only target their health but also medical aesthetics.
It's latest innovation, Sun Control is a new generation in sun protection. A system that clearly reveals how long a person is safe in the sun with a sun screen agent.
Sun Control has been granted patent protection in the major territories US, EU, Australia and Mexico.

Background

Our product portfolio is mainly focused to heal, improve, protect and repair the dermal tissue. Year 2010 New Medic Era started a project to resolve the increase of skin cancer among the predominately fair-skinned population. There is a widespread and ever-increasing need for protection against UV radiation, due to the risk of skin cancer.

The SPF (sun protection factor) used worldwide today, is a misleading standard. It was invented in the 1960s under the premises that the SPF is between 1 to 10, to calculate a safe time in the sun. With the higher SPFs of today, up to 100, the calculating standard does not work. It was time for a paradigm shift.

What makes us unique?

Sun Control enables a person to know the time they are safe in the sun. The invention relates to a container with a sunscreen agent, equipped with a sun sensor of photochromic ink under the cap. When the cap is removed, the sensor is exposed to sunlight and contributes a quick reaction of the photochromic ink to the current UV intensity. The ink switching to the corresponding hue. The container further comprises a color-reference range for comparative reading of the sensor hue to enable the determination of UV intensity.
Further, the container is provided with a skin-type indicator for determining the skin type of a specific user, and a time indicator for determining the period of time during which a person of a specific skin type can expose his or her skin to solar radiation at said determined UV intensity without suffering from sunburn.
The combination of the sun sensor and time-table, along with information on the skin type and the sun-protection factor of the lotion, results in the unique product and protection.
A user can easily and quickly determine for how long it is safe to stay in the sun without getting sunburn. Being able to tan safely is a need for new and improved products for the purpose. Just the U.S. sun care market size is expected to reach USD 2.68 billion by 2025, according to a new report by Grand View Research, Inc.

Why should you meet us?

We are an inspiring company in a sector where life science has bonded with medical aesthetics through M&A. Our products cover patient and consumer needs. We are interested in meeting investors and potential licensing partners.

HEALING, IMPROVING, PROTECTING AND REPAIRING THE DERMAL TISSUE.

Key Team

Martina Richter | President & CEO

Martin Richter | Engineer & CEO

SALSS Contact

Martina Richter,
CEO

New Medic Era AB
Karlavägen 71, 5 tr. 114 50 Stockholm

www.medicera.com

#WAR ONCA NCER

WarOnCancer is a Stockholm-based tech company on a mission to improve mental health for everyone affected by cancer. Founded by Fabian Bolin, currently in remission for acute lymphoblastic leukemia (ALL) following 900 days of chemotherapy, and long-term friend Sebastian Hermelin.

Our Products & Services

The WarOnCancer App is a social media app for patients, survivors and loved ones focused on storytelling and content creation as a driver of engagement.

Our app is available on App Store - app.waroncancer.com

By uniting the patient community on a social network, we are in a unique position to become a global provider of patient reported data to the healthcare industry and life-science industry. We have signed paying data-partnerships with six leading pharmaceutical companies within oncology and immunotherapy, and are currently working together with their experts to design a unique data-sharing module of the platform.

What makes us unique?

We believe the secret to solving the mental health problem lies in the domain of self-worth.
We have a unique take on data-sharing, which enables members who share data to transparently track who uses their data and for what reason. Rather than viewing health data and the collection of it as a burdensome process, we will gamily the concept and turn it into a value proposition for our members.

Why should you meet us?

The US is a target market for WarOnCancer, since it holds more than 50% of the patient data market today.
We're keen to build relationships with both investors and the life science industry.



IMPROVING MENTAL HEALTH FOR EVERYONE AFFECTED BY CANCER.

Key Team

Fabian Bolin | CEO

Sebastian Hermelin | COO & Head of Industry & Data Partnerships

Resad & Faris Zacina | Co-CTO's

SALSS Contact

Sebastian Hermelin, COO
+46 (0)73 500 97 60